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Over the past three decades a meaningful sequence of suc-
cesses was realized in the cardiovascular area, each resulting
from the demonstration that antihypertensive agents are ef-
fective in reducing cardiovascular morbidity and mortality.
In the early 1950s, potent agents were introduced that made
malignant hypertension and other severe forms of hyper-
tension amenable to therapy. These results demonstrated
clearly the merits of antihypertensive pharmacotherapy. With
the series of Veterans Administration multicenter studies,
effectiveness of antihypertensive therapy was further dem-
onstrated for patients whose diastolic pressures exceeded
129 mm Hg (I), then 115 through 129 mm Hg (2) and later.
90 through 114 mm Hg (3). These studies may also be
credited with a number of secondary accomplishments: I)
they established further credibility that antihypertensive
therapy should be advocated at least for all patients whose
diastolic pressures exceeded 104 mm Hg; 2) they established
the value of prospectively designed multicenter studies deal-
ing with pharmacologic agents; 3) they underscored the
necessity for a national education program to ensure that
both the medical profession and the lay public would be
aware of the disastrous and preventable consequences of
untreated hypertension and would know that the clinical
problem is eminently treatable; and 4) they provided impetus
for the establishment of several new multicenter studies that
would later demonstrate the value of the therapeutic ap-
proach initially set forth by the Veterans Administration
studies (for example, the Hypertension Detection and Fol-
low-Up Program [HDFP] and the Multiple Risk Factor In-
tervention Trial [MRFIT]). The latter was designed to show
that simultaneous reduction of a variety of risk factors will
result in reduced cardiovascular death and disability.
To be sure, the bottom-line effect, that is, a reduction
in the annual rate of cardiovascular death from 54 to 50%
(of total deaths in the United States), was not solely the
result of a more vigorous application of antihypertensive
therapy over this past decade (Fig. I). However, antihy-
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pertensive therapy was a major factor in addition to the
national awareness of the need to consume a more healthful
diet, lower excess body weight, discontinue smoking and
initiate exercise programs. Other important factors probably
included the development of improved modalities of other
cardiovascular therapy (pharmacologic and coronary bypass
surgery), coronary care units, mobile coronary units, car-
diopulmonary resuscitation and electroshock therapy.
Recent Multicenter Trials
Unfortunately, appreciation of the cardiovascular suc-
cesses emanating from several recent multicenter trials has
been clouded by certain reactionary attitudes. Some reflect
a belief that only the study treatment centers were able to
demonstrate therapeutic success through their vigorous stepped
care treatment programs with therapeutic goal pressures. Do
we believe that the decade of high blood pressure educa-
tional programs was not really that successful? I think not.
It is clear that the remarkable reduction of national cardio-
vascular mortality and the 40% reduction in deaths from
stroke were achieved by the practicing physicians through-
out our nation (4). These are the physicians who provided
the "referred care" or "usual care" for the prospective
multicenter studies. It is precisely this group of patients that
accounts for the majority of individuals with hypertension
and the majority of deaths from hypertension-related dis-
eases. Actually, the average diastolic pressure of the referred
care patients of the Hypertension Detection and Follow-up
Program (HDFP) study after 5 years of therapy was reduced
to less than 90 mm Hg, only a 4 mm Hg difference from
that in the group of patients receiving "stepped care" (5).
This is a truly remarkable response to a nationwide contin-
uing medical education effort! In contrast, the intensive
treatment offered by the stepped care approach effected a
lower treatment diastolic pressure after 5 years. This was
associated with a significantly greater reduction not only in
cardiovascular deaths but also in total (or overall) death
rates (5). Negative statements to the contrary, the patients
with mild hypertension who were treated by the stepped
care approach did, in fact, demonstrate a reduction in deaths
from myocardial infarction. This was observed in the stra-
tum I patients with mild hypertension.
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Figure 1. Mosaic of factors associated with reduced cardiovas-
cular mortal ity in the United Slates (with thanks to I. H. Page).
Pharmacotherapeutic Approach to
Mild Hypertension?
Recently, the Multiple Risk Factor Intervention Trial
(MRFIT) program reported the first results of its aggressive
therapeutic approach to reduce cardiovascular risk factors
(6). These results indicated that there were more cardio-
vascular deaths among patients with mild hypertension who
were treated intensively by the treatment centers (the "spe-
cial intervention" group) than in the community (usual care)
group. The response to these results was amazing. First,
authorities, and even the lay press, concluded that perhaps
we should " throw the baby out with the bath water." After
all, if the special intervention or stepped care approach
produced this, antihypertensive therapy may not be as sound
as we had initially thought. Unfortunately, there was no
immediate response from those with greater expertise to ask:
what might have accounted for these differences; could the
referred care and usual care groups have been doing some-
thing better; and could alternative forms of therapy have
prevented these deaths?
Role of diuretic-induced hypokalemia and arrhyth-
mias. Results showed that the increased deaths of the spe-
cial intervention group of patients with mild hypertension
(in the MRFIT study) occurred in those patients who had a
greater incidence of abnormal electrocardiograms before the
initiation of the study than the patients of the usual care
group. Of these patients with abnormal electrocardiograms,
over half demonstrated voltage changes compatible with left
ventricular hypertrophy; almost an additional one-third had
either conduction defects or rhythm disturbances (7). We
now learn from the National Heart, Lung, and Blood In-
stitute that hypokalemiaassociated with the diuretic therapy
in those patients most likely accounted for these deaths.
Thus, it is reasoned that the diuretic-induced hypokalemia
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predisposed the already abnormal heart to arrhythmias and,
therefore, sudden death. Several reports (8- 10)already have
indicated that patients treated with diuretic drugs-partic-
ularly with higher doses-demonstrated hypokalemia that
was associated with a greater frequency of cardiac arrhyth-
mias. Moreover, a recent report from our laboratory (I I)
indicated that even untreated patients with hypertension and
left ventricular hypertrophy demonstrated a greater fre-
quency of ventricular ectopic activity over a 24 hour period.
These findings should be more reason for the practicing
physician to be aware of a greater frequency of ventricular
arrhythmias in the hypertensive patient with cardiac enlarge-
ment who develops diuretic-induced hypokalemia.
Coincident with these developments, there has been a
major change in the pharmaceutical-prescribing practice of
physicians. No longer are the major tranquilizing agents the
most frequently prescribed drugs; they have been surpassed
by cardiovascular agents (agents used for the treatment of
hypertension, diuretics with potassium-retaining agents and
the beta-adrenergic receptor blocking drugs) (12). Although
the data detailing use of these agents by the referred care
or usual care physicians (of the Hypertension Detection and
Follow-Up Program [HDFPj and Multiple Risk Factor In-
tervention Trial [MRFIT) studies, respectively) are not yet
published, their wide use by the nationwide community of
practicing physicians is a matter of record (12).
Community treatment versus special intervention.
From this information it is clear that we should derive more
from the Multiple Risk Factor Intervention Trial study than
the disconcerting information that treatment of mild hyper-
tension may increase cardiovascular deaths. We must also
realize that these deaths were found primarily in the patients
with mild hypertension of the special intervention group
who had an abnormal electrocardiogram before initiation of
therapy. We should realize that patients with an abnormal
electrocardiogram were not allocated in equal numbers by
randomization into two groups. In other words, we should
know that the treated (usual care) patients treated by their
personal physicians did not have as many deaths or as many
pretreatment abnormal electrocardiograms. We should also
consider that the physicians in the community just might
have been doing something better than the therapists of the
special intervention centers. We should also realize that the
patients in the community also were concerned about risk
factors other than hypertension and they did somethingabout
them.
Nonetheless, these preliminary reports have prompted a
series of editorial comments that could be most damaging
to the overall concept of pharmacotherapy of hypertension.
To be sure, the authors (13-16) cautioned that their advice
concerns the treatmentof only mild hypertension. However,
theircautions are easy to carry over to other circumstances-
guilt by association is a common failing.
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Benefits of Pharmacotherapy in
Mild Hypertension
Let us remember that the strongest prospectively col-
lected epidemiologic data indicate no specific level of pres-
sure that defines increased cardiovascular risk. The higher
the pressure-systolic or diastolic-the greater is the risk
(17). The data from the Veterans Administration and U.S.
Public Health Service (few as they are concerning patients
whose diastolic pressures decreased to between 90 and 104
mm Hg) (3,18), the Hypertension Detection and Follow-
Up Program (4), Multiple Risk Factor Intervention Trial (5)
and Australia study (19) did demonstrate the efficacy of
pressure reduction in patients with mild hypertension.
Let us not confuse the issue with statements that in no
study did antihypertensive treatment prevent deaths from
myocardial infarction. This is truly another question which
to some extent is answerable. First, we must recall that the
average age of patients at entrance to the Veterans Admin-
istration studies was the late 40s, an age when coronary
artery lesions already occur in male Americans. Autopsy
reports of teenaged American soldiers, killed in Korea or
Vietnam, demonstrated the presence of atherosclerotic le-
sions (20,21). Second, fatal myocardial infarction was re-
duced by 46% in the stratum I stepped care patients of the
Hypertension Detection and Follow-Up Program study (5).
There were 30 stepped care patients with mild hypertension
having myocardial infarction and 56 referred care patients.
These data were even more impressive than for the total
experience of the Hypertension Detection and Follow-Up
Program. In addition, there was a 45% reduction in deaths
from cerebrovascular disease in the stepped care group with
mild hypertension (5). Another study, from Sweden (22),
demonstrated significant reduction in fatal and nonfatal
myocardial infarctions. In addition, clinicians from the Mayo
Clinic (23,24) recently reported the benefit of antihyperten-
sive therapy for survival of patients with atherosclerotic
heart disease.
Recommendations
Therefore, in these times when it is popular to discredit
established practice and belief (a characteristic not exclusive
to the field of medicine), let us maintain reason and not be
too quick to destroy well conceived and validly demon-
strated practices. We should still consider that all individuals
whose diastolic pressure exceeds 90mm Hg are at increased
cardiovascular risk. Moreover, we must still recognize that
in these individuals pressure should be reduced in order to
minimize that risk. It is not unreasonable to pursue non-
pharmacologic means to control pressure, but, in any case,
at the least these patients should remain under continuous
and close clinical observation and management. Should re-
striction of dietary sodium or reduction in body weight not
be feasible or effective for a specific patient in a reasonable
time period, there is no reason why drug treatment should
not be prescribed. With the availability of several thera-
peutic alternatives including once-daily administration of
beta-receptor blocking agents or diuretics with potassium-
retaining agents, danger of hypokalemia is not the necessary
alternative or consequence. Moreover, we have also come
to realize that there is little necessity to prescribe 100 mg
daily of hydrochlorothiazide; initiation of therapy at 25 mg
(and later, 50 mg) doses may be adequate.
Let us not reverse the remarkable downturn in cardio-
vascular and stroke mortality solely through the weight of
editorial comment. The supportive well established data
were long and hard to come by and were costly in human
contribution and dollars. Ethical practice (and our material
resources) will not permit a more ideal reexamination of
this problem. Finally, let us not impugn the results of these
studies by implying that the investigators resorted to bio-
statistical game-playing. At best, these comments directed
toward reputable professionals who were not playing games
are unfair and unfounded; and their peer-reviewed statistical
analyses may be subjected to professional questioning but
not discredit.
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